Catalent to purchase Paragon Bioservices

Catalent has bought Paragon Bioservices, a contract development and manufacturing organization for $1.2 billion. This is the second major buyout of a gene therapy manufacturer in the last three weeks.

This deal will get Catalent a newly completed commercial-scale manufacturing facility near Baltimore and position Catalent firmly to capture some of the $40 billion gene therapy market.

Click here to read the entire article.